Jardimet Tablet 5 mg + 500 mg is a fixed-dose combination of Empagliflozin and Metformin Hydrochloride, two well-established antidiabetic agents used in the management of type 2 diabetes mellitus. This combination offers complementary mechanisms of action to achieve better and sustained blood glucose control in adult patients whose diabetes is not adequately controlled with monotherapy.

Metformin Hydrochloride is considered a first-line treatment for type 2 diabetes and works primarily by reducing hepatic glucose production and improving insulin sensitivity. Empagliflozin, a Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor, lowers blood glucose by increasing urinary glucose excretion. Together, these agents provide effective glycemic control while minimizing the risk of hypoglycemia when used appropriately.

Jardimet Tablet 5 mg + 500 mg is particularly beneficial for patients requiring combination therapy to manage fasting and postprandial blood glucose levels, along with added metabolic advantages such as weight control.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Empagliflozin 5 mg

• Metformin Hydrochloride 500 mg

Therapeutic Class

• Antidiabetic Agents

• SGLT2 Inhibitor + Biguanide Combination

Indications and Uses

Jardimet Tablet 5 mg + 500 mg is indicated for:

• Treatment of type 2 diabetes mellitus in adults

• Patients inadequately controlled on metformin or empagliflozin alone

• Adjunct to diet and exercise to improve glycemic control

• Use as part of combination therapy in comprehensive diabetes management

Mechanism of Action

Metformin decreases glucose production in the liver, reduces intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues. Empagliflozin inhibits the SGLT2 transporter in the kidneys, reducing glucose reabsorption and increasing glucose elimination through urine. This dual mechanism provides effective blood sugar control without overburdening pancreatic beta cells.

Key Benefits

• Dual-action formula for enhanced glycemic control

• Targets both insulin resistance and excess glucose reabsorption

• Low risk of hypoglycemia when used without insulin or sulfonylureas

• Supports weight neutrality or modest weight reduction

• Convenient fixed-dose combination improves treatment adherence

Dosage and Administration

• Taken orally, usually once or twice daily as prescribed

• Should be taken with meals to reduce gastrointestinal side effects

• Dosage adjustment depends on patient response and renal function

• Regular monitoring of blood glucose and kidney function is advised

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis

• Use with caution in patients with renal or hepatic impairment

• Risk of dehydration; adequate fluid intake should be maintained

• Metformin-associated lactic acidosis is rare but serious

• Avoid excessive alcohol consumption during therapy

Adverse Effects

Common side effects may include nausea, diarrhea, abdominal discomfort, increased urination, urinary tract infections, or genital fungal infections. Most adverse effects are mild and tend to resolve with continued use and proper medical supervision.

Storage Conditions

• Store below 30°C in a dry place

• Protect from light and moisture

• Keep out of reach of children

Conclusion

Jardimet Tablet 5 mg + 500 mg (Empagliflozin + Metformin Hydrochloride) is an effective combination therapy for managing type 2 diabetes mellitus. By addressing multiple pathophysiological factors of diabetes, it helps achieve improved glycemic control and supports long-term metabolic health when used under medical guidance.